Showing 19 of 19 recruiting trials for “Cutaneous neuroendocrine carcinoma”
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
TIL Therapy in cSCC and MCC
RecruitingNCT07215988 ↗
Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study
👨⚕️ Claire F Verschraegen, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Jan 2026View details ↗
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
RecruitingNCT06780475 ↗
Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma
👨⚕️ Astrid Blom, MD, Dermato-oncology Department, Ambroise Paré Hospital, APHP📍 1 site📅 Started May 2025View details ↗
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
RecruitingNCT06608511 ↗
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
👨⚕️ Evan J Lipson, JHU Sidney Kimmel Comprehensive Cancer Center LAO📍 26 sites📅 Started Jul 2024View details ↗
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
👨⚕️ Carlo M Contreras, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Dec 2023View details ↗
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
A Study of CRD3874-SI in People With Solid Tumors
👨⚕️ Ciara Kelly, MBBCH BAO, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Aug 2023View details ↗
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
👨⚕️ Anna C Pavlick, BSN, MSc, DO, MBA, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine📍 3 sites📅 Started Aug 2023View details ↗
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
RecruitingNCT06536257 ↗
Personalised Immunotherapy Platform
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →